Mr David Rosenthal > Dechert LLP > New York, United States > Lawyer Profile

Dechert LLP Offices

Dechert LLP
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
NEW YORK
United States
Visit website 1 212 698 3500 1 212 698 3599

Mr David Rosenthal

David Rosenthal photo
+1 212 698 3616 david.rosenthal@dechert.com

Work Department

Corporate

Position

Partner

Career

David S. Rosenthal, co-chair of Dechert’s Global Corporate Finance and Capital Markets Practice and co-lead of the firm’s Life Sciences Practice, represents publicly and privately held corporations, investment banks, and venture capital firms focused on the life sciences and medical device, technology, media, and other growth sectors. He represents clients in corporate finance transactions, mergers and acquisitions, joint ventures, licensings and strategic alliances.

Mr. Rosenthal regularly advises issuers and investment banks in public and private offerings of equity and debt, including IPOs, secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, registered direct offerings, and PIPEs, as well as seed financings and later-stage venture capital financings. He also has particular experience counseling foreign private issuers in migrating to and listing on the U.S. stock exchanges. Mr. Rosenthal also counsels clients in general corporate matters, Securities and Exchange Commission (SEC) compliance, and corporate governance, and often acts as outside general corporate and securities counsel to both emerging and publicly traded companies. These activities have included business and corporate planning and structuring as well as other contract negotiations, and contractual and other commercial dealings.

In the mergers and acquisitions area, Mr. Rosenthal has represented buyers and sellers in leveraged and unleveraged mergers, acquisitions, and private equity transactions as well as divestitures and dispositions of business and subsidiaries. The American Lawyer selected Mr. Rosenthal as Dealmaker of the Week for his skillful representation of Inhibitex in its sale to Bristol-Myers Squibb for US$2.5 billion, which represented a 163 percent premium to the closing price of the company’s stock the day before the transaction signed, and is believed to be one of the largest premiums in deal history. 

Education

  • Wesleyan University, B.A., cum laude
  • Boston University School of Law, J.D., cum laude

Lawyer Rankings

United States > Healthcare > Life sciences

Regarded by some clients as ‘easily the best’, Dechert LLP’s global life sciences practice often handles patent and IP litigations, contentious antitrust matters, and product liability related issues. Working with a host of start-ups and mature pharmaceutical and biotech companies, Andrea Reid co-heads the team from Boston, drawing on her expertise in IP strategy and prosecution. Based in New York, the ‘truly exceptional‘ fellow co-chair David S Rosenthal maintains a corporate finance and life sciences M&A focused practice. Rosenthal routinely advises public and private investment banks and venture capital firms on IPOs and CMPOs looking to invest in life sciences and medical device companies. Also based in New York, Katherine Helm notably acts for biotech and pharmaceutical companies in biologics patent disputes before the PTAB.

United States > Finance > Capital markets: equity offerings

Dechert LLP’s capital markets practice remains closely associated with life sciences and permanent capital vehicles, including business development companies. It is also noted for cross-border offerings, including those from Latin America. Thomas Friedmann, Boston managing partner and co-chair of the capital markets group, is noted for permanent capital vehicle transactions. New York partner David S Rosenthal co-heads the capital markets group and has a long track record in life sciences transactions.

United States > Finance > Capital markets: global offerings

Dechert LLP has an established record in cross-border offerings, particularly those involving Latin America. It is also active in cross-border offerings for permanent capital vehicles and business development companies. Recently, it advised Blackstone Private Credit Fund, a closed-end management investment company and business development company, on its inaugural euro-dominated offering of €500m of 1.750% Notes due 2026. Boston’s Thomas Friedmann and New York partner David S Rosenthal, a life sciences specialist, co-chair the capital markets practice. Howard Kleinman departed for McDermott Will & Emery LLP in July 2023.

Lawyer Rankings

Top Tier Firm Rankings

Firm Rankings